Suresh Ramalingam
MD
Executive Director, Winship Cancer Institute
👥Biography 个人简介
Suresh Ramalingam led the FLAURA trial establishing first-line osimertinib as the preferred EGFR TKI for advanced NSCLC and has been a key contributor to adjuvant osimertinib development. His research on EGFR TKI resistance mechanisms and treatment sequencing has informed clinical practice. He leads one of the largest thoracic oncology programs in the United States.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Suresh Ramalingam 的研究动态
Follow Suresh Ramalingam's research updates
留下邮箱，当我们发布与 Suresh Ramalingam（Emory University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment